CROI 2020 Program and Conference Information

Oral Sessions

108 CONTRACEPTIVE IMPLANT ROLLOUT IN SOUTH AFRICA Gregory Petro , U niversity of Cape Town, Cape Town, South Africa 109 CONTRACEPTION AND HIV RISK: A CONUNDRUMNO MORE Renee Heffron , University of Washington, Seattle, WA, USA 110 THE STATE OF SRHR&HIV SERVICES FOR CIS- GENDERWOMEN: A COMMUNITY PERSPECTIVE Wame Jallow , International Treatment Preparedness Coalition, Gaborone, Botswana

CME LATE-BREAKING NEWS: UPDATE FROM THE HVTN 702 VACCINE (UHAMBO) TRIAL Ballroom B 6:10 PM - 6:45 PM On February 3, 2020 the HVTN 702 HIV vaccine efficacy trial in South Africa discontinued vaccinations because the interim review by the Data and Safety Monitoring Board reported that the vaccine candidate did not prevent HIV. There were no safety concerns. This session will provide a brief overview of the results available and provide meeting attendees with an opportunity to ask questions of the study team as they prepare for the full analysis of these data. INTRODUCTION OF HVTN 702 STUDY Lawrence Corey, Fred Hutchinson Cancer Research Center, Seattle, WA, USA PRESENTATION OF HVTN 702 STUDY DATA Glenda E. Gray, University of the Witwatersrand, Johannesburg, South Africa Moderator Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA Panelists Lawrence Corey, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Glenda E. Gray, University of the Witwatersrand, Johannesburg, South Africa Steven F. Wakefield, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Please refer to the CROI Mobile App for more details.

Oral Sessions • Tuesday

CROI 2020 54